Taspoglutide is a glucagon-like peptide-1 agonist was studied in phase III clinical trials for the treatment patients with type 2 diabetes. However, in September 2010 Roche halted Phase III clinical trials due to gastrointestinal intolerability and serious hypersensitivity reactions experienced by some trial participants.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. | 2019-09 |
|
| Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. | 2017-04 |
|
| Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects. | 2015-11-01 |
|
| Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials. | 2015-07 |
|
| Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. | 2015-05 |
|
| Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. | 2009-07 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98085
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB32528
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
56842233
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
C152518
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
m10479
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
C541736
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
2PHK27IP3B
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
8975
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
275371-94-3
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
TASPOGLUTIDE
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
DB14027
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107860
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
100000124402
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
WW-10
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
